ELLIPTIC LABORATORIES ASA (ELABS.OL) Stock Fundamental Analysis

OSL:ELABS • NO0010722283

5.2 NOK
-0.06 (-1.14%)
Last: Feb 20, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

4

Overall ELABS gets a fundamental rating of 4 out of 10. We evaluated ELABS against 117 industry peers in the Software industry. While ELABS seems to be doing ok healthwise, there are quite some concerns on its profitability. ELABS is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one!


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • ELABS had negative earnings in the past year.
  • In the past year ELABS had a positive cash flow from operations.
  • ELABS had negative earnings in 4 of the past 5 years.
  • ELABS had a negative operating cash flow in each of the past 5 years.
ELABS.OL Yearly Net Income VS EBIT VS OCF VS FCFELABS.OL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M

1.2 Ratios

  • ELABS's Return On Assets of -1.61% is on the low side compared to the rest of the industry. ELABS is outperformed by 60.68% of its industry peers.
  • The Return On Equity of ELABS (-1.74%) is comparable to the rest of the industry.
  • ELABS has a Return On Invested Capital of 1.48%. This is comparable to the rest of the industry: ELABS outperforms 49.57% of its industry peers.
Industry RankSector Rank
ROA -1.61%
ROE -1.74%
ROIC 1.48%
ROA(3y)-5.97%
ROA(5y)-5.33%
ROE(3y)-6.62%
ROE(5y)-5.96%
ROIC(3y)N/A
ROIC(5y)N/A
ELABS.OL Yearly ROA, ROE, ROICELABS.OL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 -20 -40

1.3 Margins

  • ELABS has a Operating Margin of 4.35%. This is comparable to the rest of the industry: ELABS outperforms 52.14% of its industry peers.
  • The Profit Margin and Gross Margin are not available for ELABS so they could not be analyzed.
Industry RankSector Rank
OM 4.35%
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ELABS.OL Yearly Profit, Operating, Gross MarginsELABS.OL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. Health

2.1 Basic Checks

  • ELABS has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • The number of shares outstanding for ELABS has been increased compared to 1 year ago.
  • ELABS has more shares outstanding than it did 5 years ago.
  • ELABS has a better debt/assets ratio than last year.
ELABS.OL Yearly Shares OutstandingELABS.OL Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
ELABS.OL Yearly Total Debt VS Total AssetsELABS.OL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

  • A Debt/Equity ratio of 0.03 indicates that ELABS is not too dependend on debt financing.
  • ELABS's Debt to Equity ratio of 0.03 is amongst the best of the industry. ELABS outperforms 81.20% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Altman-Z N/A
ROIC/WACC0.16
WACC9.18%
ELABS.OL Yearly LT Debt VS Equity VS FCFELABS.OL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M

2.3 Liquidity

  • ELABS has a Current Ratio of 9.66. This indicates that ELABS is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 9.66, ELABS belongs to the top of the industry, outperforming 94.02% of the companies in the same industry.
  • A Quick Ratio of 9.66 indicates that ELABS has no problem at all paying its short term obligations.
  • ELABS has a Quick ratio of 9.66. This is amongst the best in the industry. ELABS outperforms 94.02% of its industry peers.
Industry RankSector Rank
Current Ratio 9.66
Quick Ratio 9.66
ELABS.OL Yearly Current Assets VS Current LiabilitesELABS.OL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 66.67% over the past year.
  • The Revenue has grown by 50.76% in the past year. This is a very strong growth!
  • Measured over the past years, ELABS shows a very strong growth in Revenue. The Revenue has been growing by 28.29% on average per year.
EPS 1Y (TTM)66.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%175%
Revenue 1Y (TTM)50.76%
Revenue growth 3Y34.19%
Revenue growth 5Y28.29%
Sales Q2Q%49.72%

3.2 Future

  • ELABS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 124.60% yearly.
  • ELABS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 27.54% yearly.
EPS Next Y80.25%
EPS Next 2Y148.6%
EPS Next 3Y124.6%
EPS Next 5YN/A
Revenue Next Year23.81%
Revenue Next 2Y30.32%
Revenue Next 3Y33.38%
Revenue Next 5Y27.54%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
ELABS.OL Yearly Revenue VS EstimatesELABS.OL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2029 2030 2031 2032 100M 200M 300M 400M 500M
ELABS.OL Yearly EPS VS EstimatesELABS.OL Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 0 0.2 -0.2 0.4 0.6 0.8

More info and screens

Find the best growth stocksShow best growing peers

4

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ELABS. In the last year negative earnings were reported.
  • The Price/Forward Earnings ratio is 10.52, which indicates a very decent valuation of ELABS.
  • 89.74% of the companies in the same industry are more expensive than ELABS, based on the Price/Forward Earnings ratio.
  • ELABS is valuated cheaply when we compare the Price/Forward Earnings ratio to 28.06, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 10.52
ELABS.OL Price Earnings VS Forward Price EarningsELABS.OL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 -40 -60

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of ELABS is on the same level as its industry peers.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 16.63
ELABS.OL Per share dataELABS.OL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2

4.3 Compensation for Growth

  • ELABS's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • ELABS's earnings are expected to grow with 124.60% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y148.6%
EPS Next 3Y124.6%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • ELABS does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ELLIPTIC LABORATORIES ASA

OSL:ELABS (2/20/2026, 7:00:00 PM)

5.2

-0.06 (-1.14%)

Chartmill FA Rating
GICS IndustryGroupSoftware & Services
GICS IndustrySoftware
Earnings (Last)11-20
Earnings (Next)N/A
Inst Owners33.51%
Inst Owner ChangeN/A
Ins Owners8.59%
Ins Owner ChangeN/A
Market Cap547.51M
Revenue(TTM)141.05M
Net Income(TTM)-5.42M
Analysts84.44
Price Target19.38 (272.69%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-163.33%
Min EPS beat(2)-241.22%
Max EPS beat(2)-85.44%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-39.83%
Min Revenue beat(2)-45.84%
Max Revenue beat(2)-33.83%
Revenue beat(4)1
Avg Revenue beat(4)-19.07%
Min Revenue beat(4)-45.84%
Max Revenue beat(4)13.5%
Revenue beat(8)1
Avg Revenue beat(8)-24.34%
Revenue beat(12)2
Avg Revenue beat(12)-24.95%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)63.64%
EPS NY rev (1m)0%
EPS NY rev (3m)55.56%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)12.96%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-7.14%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 10.52
P/S 3.88
P/FCF N/A
P/OCF 22.65
P/B 1.76
P/tB 2.29
EV/EBITDA 16.63
EPS(TTM)-0.07
EYN/A
EPS(NY)0.49
Fwd EY9.51%
FCF(TTM)-0.04
FCFYN/A
OCF(TTM)0.23
OCFY4.41%
SpS1.34
BVpS2.96
TBVpS2.27
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -1.61%
ROE -1.74%
ROCE 1.92%
ROIC 1.48%
ROICexc 1.77%
ROICexgc 2.43%
OM 4.35%
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-5.97%
ROA(5y)-5.33%
ROE(3y)-6.62%
ROE(5y)-5.96%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score7
Asset Turnover0.42
Health
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Debt/EBITDA 0.27
Cap/Depr 115.92%
Cap/Sales 20.34%
Interest Coverage 4.14
Cash Conversion 78.25%
Profit Quality N/A
Current Ratio 9.66
Quick Ratio 9.66
Altman-Z N/A
F-Score7
WACC9.18%
ROIC/WACC0.16
Cap/Depr(3y)167.84%
Cap/Depr(5y)198.62%
Cap/Sales(3y)35.14%
Cap/Sales(5y)37.53%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)66.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%175%
EPS Next Y80.25%
EPS Next 2Y148.6%
EPS Next 3Y124.6%
EPS Next 5YN/A
Revenue 1Y (TTM)50.76%
Revenue growth 3Y34.19%
Revenue growth 5Y28.29%
Sales Q2Q%49.72%
Revenue Next Year23.81%
Revenue Next 2Y30.32%
Revenue Next 3Y33.38%
Revenue Next 5Y27.54%
EBIT growth 1Y122.01%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year5814.29%
EBIT Next 3Y493.58%
EBIT Next 5Y223.55%
FCF growth 1Y94.22%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y146.64%
OCF growth 3YN/A
OCF growth 5YN/A

ELLIPTIC LABORATORIES ASA / ELABS.OL FAQ

Can you provide the ChartMill fundamental rating for ELLIPTIC LABORATORIES ASA?

ChartMill assigns a fundamental rating of 4 / 10 to ELABS.OL.


Can you provide the valuation status for ELLIPTIC LABORATORIES ASA?

ChartMill assigns a valuation rating of 4 / 10 to ELLIPTIC LABORATORIES ASA (ELABS.OL). This can be considered as Fairly Valued.


Can you provide the profitability details for ELLIPTIC LABORATORIES ASA?

ELLIPTIC LABORATORIES ASA (ELABS.OL) has a profitability rating of 1 / 10.


What is the expected EPS growth for ELLIPTIC LABORATORIES ASA (ELABS.OL) stock?

The Earnings per Share (EPS) of ELLIPTIC LABORATORIES ASA (ELABS.OL) is expected to grow by 80.25% in the next year.